{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:18:36Z","timestamp":1792671516717,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":425,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1111\/1469-0691.12320","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T04:49:09Z","timestamp":1380689349000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults"],"prefix":"10.1016","volume":"19","author":[{"given":"P.","family":"Durando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12320_bib1","author":"World Health Organization"},{"key":"10.1111\/1469-0691.12320_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2318-10-44","article-title":"Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study","volume":"10","author":"Krueger","year":"2010","journal-title":"BMC Geriatr"},{"key":"10.1111\/1469-0691.12320_bib3","series-title":"Epidemiology and prevention of vaccine preventable diseases. The pink book","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1111\/1469-0691.12320_bib4","series-title":"Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data","author":"European Centre for Disease Prevention and Control","year":"2011"},{"key":"10.1111\/1469-0691.12320_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1017\/S0950268806007199","article-title":"Burden of paediatric invasive pneumococcal disease in Europe, 2005","volume":"135","author":"McIntosh","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1111\/1469-0691.12320_bib7","series-title":"Annual epidemiological report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data","author":"European Centre for Disease Prevention and Control","year":"2012"},{"key":"10.1111\/1469-0691.12320_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O'Brien","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12320_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0029-1202941","article-title":"Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network","volume":"30","author":"Welte","year":"2009","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1111\/1469-0691.12320_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1111\/1469-0691.12320_bib11","author":"World Health Organization"},{"key":"10.1111\/1469-0691.12320_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/infdis\/jis240","article-title":"Aging population and future burden of pneumococcal pneumonia in the United States","volume":"205","author":"Wroe","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib13","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.vaccine.2010.05.030","article-title":"Clinical and economic burden of pneumococcal disease in older US adults","volume":"28","author":"Weycker","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1469-0691.2012.03943.x","article-title":"A century of pneumococcal vaccination research in humans","volume":"18","author":"Grabenstein","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12320_bib15","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1111\/1469-0691.12320_bib16","author":"European Medicines Agency"},{"key":"10.1111\/1469-0691.12320_bib17","author":"European Medicines Agency"},{"key":"10.1111\/1469-0691.12320_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/1469-0691.12320_bib19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/1469-0691.12320_bib20","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1111\/1469-0691.12320_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06673.x","article-title":"Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine","volume":"1263","author":"Gruber","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/1469-0691.12320_bib22","author":"Euvac"},{"key":"10.1111\/1469-0691.12320_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12325-013-0007-6","article-title":"The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review","volume":"30","author":"Myint","year":"2013","journal-title":"Adv Ther"},{"key":"10.1111\/1469-0691.12320_bib24","author":"PediSurv"},{"key":"10.1111\/1469-0691.12320_bib25","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2012.06.068","article-title":"Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children","volume":"30","author":"van der Linden","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib26","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3201\/eid1605.091223","article-title":"Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands","volume":"16","author":"Rodenburg","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.vaccine.2009.12.054","article-title":"Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule","volume":"28","author":"Vestrheim","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/thx.2010.137802","article-title":"Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997\u20132008","volume":"65","author":"Koshy","year":"2010","journal-title":"Thorax"},{"key":"10.1111\/1469-0691.12320_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","article-title":"Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis","volume":"369","author":"Grijalva","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12320_bib30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1542\/peds.2007-1565","article-title":"Trends in otitis media treatment failure and relapse","volume":"121","author":"Sox","year":"2008","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12320_bib31","doi-asserted-by":"crossref","first-page":"e1165","DOI":"10.1542\/peds.2007-0037","article-title":"Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001\u20132005 National Immunization Survey","volume":"120","author":"Smith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12320_bib32","first-page":"1","article-title":"Acute otitis media: management and surveillance in an era of pneumococcal resistance. Drug-Resistant Streptococcus Pneumoniae Therapeutic Working Group","volume":"24","author":"Dowell","year":"1999","journal-title":"Nurse Pract"},{"key":"10.1111\/1469-0691.12320_bib33","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/archpedi.161.12.1162","article-title":"Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States","volume":"161","author":"Zhou","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/1469-0691.12320_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/INF.0b013e31821038d9","article-title":"The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea","volume":"30","author":"Stamboulidis","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/1469-0691.12320_bib35","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/j.vaccine.2009.01.052","article-title":"Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy","volume":"27","author":"Durando","year":"2009","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1651-2227.2011.02332.x","article-title":"Pneumococcal vaccination in children at risk of developing recurrent acute otitis media \u2013 a randomized study","volume":"100","author":"Gisselsson-Sol\u00e9n","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1111\/1469-0691.12320_bib37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"key":"10.1111\/1469-0691.12320_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3201\/eid1704.101115","article-title":"Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands","volume":"17","author":"Spijkerman","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib39","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1016\/j.vaccine.2011.04.004","article-title":"Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children","volume":"29","author":"Tocheva","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib40","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.vaccine.2012.01.067","article-title":"Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy","volume":"30","author":"Ansaldi","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib41","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/j.vaccine.2010.04.020","article-title":"Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development","volume":"28","author":"Reinert","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib42","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jama.2010.1290","article-title":"Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains","volume":"304","author":"van Gils","year":"2010","journal-title":"JAMA"},{"key":"10.1111\/1469-0691.12320_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/JCM.01454-08","article-title":"Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007","volume":"47","author":"Fenoll","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1111\/1469-0691.12320_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1099\/jmm.0.023135-0","article-title":"Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England","volume":"60","author":"Foster","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1111\/1469-0691.12320_bib46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1469-0691.2009.02904.x","article-title":"Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain","volume":"15","author":"Guevara","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12320_bib47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5694\/j.1326-5377.2010.tb03965.x","article-title":"Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001\u20132009","volume":"193","author":"Hanna","year":"2010","journal-title":"Med J Aust"},{"key":"10.1111\/1469-0691.12320_bib48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/652440","article-title":"The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes","volume":"50","author":"Lehmann","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib49","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.297.16.1784","article-title":"Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage","volume":"297","author":"Singleton","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/1469-0691.12320_bib50","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid1811.120329","article-title":"Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands","volume":"18","author":"van Deursen","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib51","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12320_bib52","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.vaccine.2011.09.112","article-title":"Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib53","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.vaccine.2009.12.026","article-title":"The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000\u20132007","volume":"28","author":"Bettinger","year":"2010","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib54","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","article-title":"Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines","volume":"14","author":"Isaacman","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1111\/1469-0691.12320_bib55","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1016\/j.vaccine.2012.03.060","article-title":"Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme","volume":"30","author":"Ingels","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12320_bib56","first-page":"378","article-title":"Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults","volume":"66","author":"Hak","year":"2008","journal-title":"Neth J Med"},{"key":"10.1111\/1469-0691.12320_bib57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","article-title":"A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults","volume":"362","author":"French","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12320_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000422.pub3","article-title":"Vaccines for preventing pneumococcal infection in adults","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/1469-0691.12320_bib59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijantimicag.2008.01.021","article-title":"Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species","volume":"32","author":"Pletz","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/1469-0691.12320_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1586\/erv.10.145","article-title":"Global prevailing and emerging pediatric pneumococcal serotypes","volume":"10","author":"McIntosh","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1111\/1469-0691.12320_bib61","first-page":"373","article-title":"23-valent pneumococcal polysaccharide vaccine. WHO position paper","volume":"83","author":"World Health Organization","year":"2008","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14614117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14614117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:13:15Z","timestamp":1761117195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14614117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":61,"alternative-id":["S1198743X14614117"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12320","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/1469-0691.12320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}